Trials / Completed
CompletedNCT00076011
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
Phase 2 Study of AG 013736 as Second-Line Treatment in Patients With Metastatic Renal Cell Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this protocol is to determine the activity of AG 013736 in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor |
Timeline
- Start date
- 2003-10-01
- Primary completion
- 2007-02-01
- Completion
- 2007-02-01
- First posted
- 2004-01-14
- Last updated
- 2012-06-26
- Results posted
- 2012-03-19
Locations
9 sites across 3 countries: United States, France, Germany
Source: ClinicalTrials.gov record NCT00076011. Inclusion in this directory is not an endorsement.